Tag: year

SINGAPORE, July 08, 2025 (GLOBE NEWSWIRE) -- Valeura Energy Inc. (TSX:VLE, OTCQX:VLERF) (“Valeura” or the “Company”) is pleased to provide an update on Q2 2025 operations.

Aspocomp Group Plc, Investor News, July 8, 2025, at 9:00 a.m. Finnish time

Aspocomp will publish its Half-Year Interim Report 2025 on Thursday, July 17, 2025 at around 9:00 a.m. Finnish time.

Aspocomp’s CEO Manu Skyttä will present Half-Year Interim Report 2025 in a webcast on the same day starting at 1:00 p.m. Finnish time. The webcast will be held in Finnish and can be accessed at https://aspocomp.events.inderes.com/q2-2025.

Questions are requested to be submitted in writing via the chat functionality of the webcast portal.

The presentation material and a recording of the webcast (in Finnish) will be available at Aspocomp’s website https://aspocomp.com/investors/interim-reports/reports/.


For further information, please contact Manu Skyttä, President and CEO,
tel. +358 20 775 6860, manu.skytta(at)aspocomp.com.


Aspocomp – heart of your technology

A printed circuit board (PCB) is used for electrical interconnection and as a component assembly platform in electronic devices. Aspocomp provides PCB technology design, testing and logistics services over the entire lifecycle of a product. The company’s own production and extensive international partner network guarantee cost-effectiveness and reliable deliveries.

Aspocomp’s customers are companies that design and manufacture telecommunication systems and equipment, automotive and industrial electronics, and systems for testing semiconductor components for security technology. The company has customers around the world and most of its net sales are generated by exports.

Aspocomp is headquartered in Espoo and its plant is in Oulu, one of Finland’s major technology hubs.

www.aspocomp.com

Basel, July 8, 2025 – Novartis today announced Coartem^® (artemether-lumefantrine) Baby has been approved by Swissmedic as the first malaria medicine for newborns and young infants. The new treatment, also known as Riamet^® Baby in some countries, was developed in collaboration with Medicines for Malaria Venture (MMV) to treat the potentially deadly mosquito-borne disease.

The group’s unaudited consolidated revenue decreased in the second quarter of 2025 by 9% year-over-year to €3,440 thousand (Q2 2024: €3,782 thousand). Unaudited consolidated total revenues for the first six months of 2025 decreased by 9% to €7,120 thousand (H1 2024: €7,809 thousand).